Phase II proof of concept clinical trial of voclosporin in the patients with focal segmental glomerulosclerosis (FSGS)and minimal change disease (MCD).

Trial Profile

Phase II proof of concept clinical trial of voclosporin in the patients with focal segmental glomerulosclerosis (FSGS)and minimal change disease (MCD).

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Focal segmental glomerulosclerosis; Nephrotic syndrome
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2017 Planned initiation date changed to 1 Jan 2018.
    • 27 Oct 2017 New trial record
    • 20 Oct 2017 According to an Aurinia Pharmaceuticals media release, this trial is expected to begin in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top